Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All studies

Ripretinib

INTRIGUE

Deciphera Pharmaceuticals · Phase 3 · Active, not recruiting · Enrollment 453

NCT03673501

Catalyst Primary completion. 09.01.2021. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

ArmPopulationDoseEstimandComparatorEfficacy
Ripretinib 150 mgGIST after imatinib (ITT n = 226)150 mgITTsunitinib 50 mg 4/2median progression-free survival (IRR), ITT: 8 months, primary analysisprogression-free survival hazard ratio vs sunitinib, ITT: 1.05 HR, primary analysis; not significantmedian progression-free survival, KIT exon 11 ITT: 8.3 months, primary analysisobjective response rate, KIT exon 11 ITT: 23.9%, primary analysis; nominal P = .03median PFS, exploratory ctDNA KIT exon 11 + 17/18 only: 14.2 months, exploratory, Exploratory ctDNA analysis (Heinrich, Nat Med 2024); nominal P
Sunitinib 50 mg 4/2GIST after imatinib (ITT n = 227)50 mgITTn/rmedian progression-free survival (IRR), ITT: 8.3 months, primary analysismedian progression-free survival, KIT exon 11 ITT: 7 months, primary analysisobjective response rate, KIT exon 11 ITT: 14.6%, primary analysismedian PFS, exploratory ctDNA KIT exon 11 + 17/18 only: 1.5 months, exploratorymedian PFS, exploratory ctDNA KIT exon 11 + 13/14 (sunitinib vs ripretinib 4.0): 15 months, exploratory